• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, June 26

Aurobindo Pharma Ltd has announced it has received tentative approval from the US Food and Drug Administration (USFDA) for Quinapril Hydrochloride and Hydrochlorothiazide tablets 10mg/12.5mg and 20mg/25mg.

With this the Hyderabad-based pharma major's product basket for the US market has gone up to 45, according to a notice to the stock exchanges. The drug is indicated for the treatment of hypertension. Quinapril Hydrochloride and Hydrochlorothiazide tablets 10mg/12.5mg and 20mg/25mg are the generic equivalent of Accuretic tablets of Pfizer Pharmaceuticals Ltd. This is the company's fifth anti-hypertensive (medicines regulating blood pressure) bagging USFDA nod, the release added.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
TCS to provide solution for Ferrari's F1 cars

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line